Minocycline hydrochloride ER is under clinical development by Promius Pharma and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Minocycline hydrochloride ER’s likelihood of approval (LoA) and phase transition for Rosacea took place on 30 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Minocycline hydrochloride ER Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Minocycline hydrochloride ER overview
Minocycline hydrochloride is under development for the treatment of rosacea. The drug candidate is a small molecule and acts by targeting 16S ribosomal subunit. The drug candidate is administered orally as an extended release capsule.
Promius Pharma overview
Promius Pharma, a subsidiary of Dr. Reddy’s Laboratories Ltd, is a designer of personal and practical health care solutions that provides dermatology and neurology products. The company provides dermatology and neurology products. Its products include clocortolone pivalate, promiseb topical cream, betamethasone dipropionate, triamcinolone acetonide ointment USP and sumatriptan injection. Promius Pharma’s promiseb topical cream is used for the treatment of seborrheic dermatitis. The company has operational research and development laboratories for product ideation, product formulation, and analytics and testing. Promius Pharma is headquartered in Princeton, New Jersey, the US.
Quick View Minocycline hydrochloride ER LOA Data
|Highest Development Stage|